Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 7/20 | 0.44 |
| ▸ | HSP90AB1 known ✓ | P08238 | 2/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.40 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.40 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | WDR5 | P61964 | 3/20 | 0.42 |
| ▸ | ATP4A | P20648 | 3/20 | 0.42 |
| ▸ | ATP4B | P51164 | 3/20 | 0.42 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | BRS3 | P32247 | 2/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.41 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382857 | 0.98 | AGXT (0.66) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| SCHEMBL1060082 | 0.98 | AGXT (0.66) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| Hydrochloric Acid SCHEMBL8063817 | 0.92 | AGXT (0.55) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| SCHEMBL3802902 | 0.87 | AGXT (0.54) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| Hydrochloric Acid SCHEMBL29385728 | 0.83 | AGXT (0.62) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| Hydrochloric Acid SCHEMBL28313021 | 0.83 | AGXT (0.62) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| Hydrochloric Acid SCHEMBL1061557 | 0.83 | AGXT (0.67) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| Hydrochloric Acid SCHEMBL311423 | 0.83 | AGXT (0.62) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| SCHEMBL8910240 | 0.83 | AGXT (0.49) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A | |
| SCHEMBL154027 | 0.82 | AGXT (0.66) | AGXTHSP90AA1HSP90AB1PDE10AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842953-A1 | Process for the preparation of esomeprazole magnesium dihydrate | Cipla Limited (IN) | 2015-03-04 | — | — | EP | claimed |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2013-06-13 | — | — | US | claimed |
| US-20100113526-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | claimed |
| EP-2125783-A2 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE | Cipla Limited (IN) | 2009-12-02 | — | — | EP | claimed |
| WO-2008102145-A2 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE | CIPLA LIMITED (IN) | 2008-08-28 | — | — | WO | claimed |
| CN-116410179-B | Preparation method of proton pump inhibitor thioether intermediate compound | 山东新时代药业有限公司 | 2025-10-28 | — | — | CN | disclosed |
| CN-115227656-B | Preparation method of omeprazole sodium for injection | 海南锦瑞制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116410179-A | Preparation method of proton pump inhibitor thioether intermediate compound | 山东新时代药业有限公司 | 2023-07-11 | — | — | CN | disclosed |
| EP-2842953-A1 | Process for the preparation of esomeprazole magnesium dihydrate | Cipla Limited (IN) | 2015-03-04 | — | — | EP | disclosed |
| EP-2186807-B1 | Process for the preparation of esomeprazole magnesium dihydrate | CIPLA LTD (IN) | 2015-01-07 | — | — | EP | disclosed |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CIPLA LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| US-8394963-B2 | Process for the preparation of esomeprazole magnesium dihydrate | CIPLA LIMITED (IN) | 2013-03-12 | — | — | US | disclosed |
| EP-0134400-B1 | FLUOROALKOXYSUBSTITUTED PYRIDYLMETHYLTHIO-(OR SULFINYL-)BENZIMIDAZOLES HAVING A SECRETOLYTIC ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1993-03-24 | — | — | EP | disclosed |
| EP-0127763-B1 | TRICYCLIC ETHERS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4560693-A | ANTISECRETORY, ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1985-12-24 | — | — | US | disclosed |
| US-4555518-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1985-11-26 | — | — | US | disclosed |
| EP-0134400-A2 | Fluoroalkoxysubstituted pyridylmethylthio-(or sulfinyl-)benzimidazoles having a secretolytic activity | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
| EP-0127763-A1 | Tricyclic ethers, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1984-12-12 | — | — | EP | disclosed |
| US-4472409-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-09-18 | — | — | US | disclosed |
| EP-0080602-A1 | Substituted benzimidazoles, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113526-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CYP2D6, TPMT, CYP3A4 | HSP90AA1 1849/4885HSP90AB1 1754/4885CHRM2 2024/4885 |
| US-20130150587-A1 | Process for the Preparation of Esomeprazole Magnesium Dihydrate | CYP2D6, TPMT, CYP3A4 | HSP90AA1 1849/4885HSP90AB1 1754/4885CHRM2 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.